Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility StudyLaetitia E. Lamberts, Gooitzen M. van Dam, Maximillian Koch et al.|Clinical Cancer Research|2016Cited by 289
Improved overall survival after contralateral risk‐reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysisB.A.M. Heemskerk-Gerritsen, Caroline Seynaeve, Matti A. Rookus et al.|International Journal of Cancer|2014Cited by 215
Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast CancerMaximilian Koch, Vasilis Ntziachristos, Bert van der Vegt et al.|Cancer Research|2016Cited by 43
A retrospective analysis of the diagnostic performance of 11C-choline PET/CT for detection of hyperfunctioning parathyroid glands after prior negative or discordant imaging in primary hyperparathyroidismMilou E. Noltes, Adrienne H. Brouwers, Schelto Kruijff et al.|EJNMMI Research|2021Cited by 24
Data from Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast CancerMaximilian Koch, Vasilis Ntziachristos, Johannes S. de Jong et al.|Unknown|2023Cited by 0